Investigating long-term effects of COVID-19

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The EuCARE-POSTCOVID study is an observational multicenter initiative that enrolls patients who have recovered from the acute phase of COVID-19 to explore the prevalence and predictors of post COVID-19 condition. This study will utilize both retrospective data from existing post COVID-19 outpatient services and a prospective cohort approach. A multidisciplinary team, including clinicians and epidemiologists, will analyze the clinical course and long-term outcomes of COVID-19 patients, focusing on the persistence of symptoms that may arise after recovery. The study aims to provide insights into the impact of different viral variants and the effectiveness of various containment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients, \>18 years old;
* Confirmed diagnosis of COVID-19 disease (positive SARS CoV-2 RNA on naso- pharyngeal swab or upper respiratory sample);
* Mild COVID-19 disease without hospital admission or moderate/severe disease requiring hospital admission for COVID-19 or hospitalization for other medical issues with a positive SARS CoV-2 RNA sample;
* Informed consent for the study.

Exclusion Criteria:

* death during hospitalization:
* patient's decline to participate in the study.

Where it's running

• University Hospital Heinrich Heine
  Düsseldorf, Germany Recruiting
• Policlinico "Tor Vergata", Università degli Studi di Roma TOR VERGATA
  Rome, Lazio, Italy Recruiting
• ASST Santi Paolo e Carlo
  Milan, Lombardy, Italy Recruiting
• Vilnius University Hospital, Santaros Klinikos
  Vilnius, Lithuania Recruiting
• Regional Hospital Dr. Juan Graham Casasús
  Villahermosa, Tabasco, Mexico Recruiting
• Centro Hospitalar de Lisboa Ocidental
  Lisbon, Portugal Recruiting

Study contacts

• Study coordinator: Francesca Incardona, Dr
• Email: francesca.incardona@euresist.org
• Phone: +393356112830

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.